Biotech
Nilo Therapeutics
Nilo Therapeutics raises $101M Series A at $450M valuation
$101M
Total Raised
Series A
Latest Round
2023
Founded
60+
Employees
New York, NY
1 min read
Quick Facts
Valuation
$450M
Latest Round Size
$101M
Latest Round Date
October 2025
Nilo Therapeutics: Series A Funding Round
Nilo Therapeutics has successfully raised $101M in Series A funding, reaching a valuation of $450M.
Company Overview
Developing therapies based on neuro-immunology research
Funding Details
The Series A round was led by Boxer Capital, with participation from Perceptive Advisors.
Company Information
- Headquarters: New York, NY
- Founded: 2023
- Employees: 60+
- Category: Biotech
Investment
Nilo Therapeutics plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Boxer Capital: Verified investor in Series A
- Perceptive Advisors: Verified investor in Series A
Key Investors
Boxer Capital
Lead Investor
Verified investor in Series A
Perceptive Advisors
Investor
Verified investor in Series A
About the Author
Editorial Team
Curated funding news from verified sources
Related Company Reports
Biotech
Orna Therapeutics
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Emma Rodriguez
Oct 23, 2025
0 min read•$251M Series B
Biotech
Forge Biologics
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Sarah Kim
Oct 23, 2025
0 min read•$120M Series C
Biotech
Vir Biotechnology
Vir Biotechnology Raises $250M
Clinical-stage immunology company developing treatments for infectious diseases including COVID-19, hepatitis B, and influenza
Sarah Kim
Oct 23, 2025
0 min read•$250M